The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Psychedelics and the essential importance of context
Abstract
Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion piece, we draw attention to a long-recognised component of the psychedelic treatment model, namely ‘set’ and ‘setting’ – subsumed here under the umbrella term ‘context’. We highlight: (a) the pharmacological mechanisms of classic psychedelics (5-HT2A receptor agonism and associated plasticity) that we believe render their effects exceptionally sensitive to context, (b) a study design for testing assumptions regarding positive interactions between psychedelics and context, and (c) new findings from our group regarding contextual determinants of the quality of a psychedelic experience and how acute experience predicts subsequent long-term mental health outcomes. We hope that this article can: (a) inform on good practice in psychedelic research, (b) provide a roadmap for optimising treatment models, and (c) help tackle unhelpful stigma still surrounding these compounds, while developing an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The psychedelic experience comes with an increased sensitivity to internal and external stimuli.”
In the citing paper
“It follows that the general context of psychedelic administration fundamentally shapes drug response and hence safety, as well as potentially therapeutic efficacy [9, 88].”
In the citing paper
“This highlights the frequent clinical observation that patients may need particularly intensive supportive care during, as well as after psychedelic experiences (Carhart-Harris et al., 2018).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Carhart-Harris et al., 2018
In the citing paper
“Psychedelic experiences vary depending not only on individual characteristics, such as health status, but also on the type of preparation available, intentions agreed upon before the experience, and the environment in which the experience takes place (Carhart-Harris et al., 2018; Golden et al., 2022).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Carhart-Harris et al., 2018
In the citing paper
“It has long been recognised that both set (the mindset of the participant, including their expectations, assumptions and intentions for the psychedelic experience, as well as stable variables such as personality and the presence of psychopathology) and setting (the physical, social and cultural environment in which the experience occurs) have the potential to greatly impact the outcomes of the Psy”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [43]
In the citing paper
“Contextual factors, such as the environment in which the experience takes place (setting), the mindset of the individual (set), and the support available after the experience (integration and setting), have a huge impact on the effects of psychedelics (85–88).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [85]
In the citing paper
“Differences in set and setting, which involve factors such as opportunity for preparation, guidance and integration by a trained guide, have been extensively shown to greatly influence the acute psychedelic experience (136, 137).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [136]
In the citing paper
“Changes in the ratings of subjective measures that were observed in the present study are not necessarily related to a pharmacological effect of 5-MeO-DMT, but could have resulted from uncontrolled variables such as response expectancy of the participants prior to and after the session or the set and setting of drug administration (Carhart-Harris et al. 2018; Hartogsohn 2016).”
From Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment (2020) · cites this paper as Carhart-Harris et al. 2018
Citations
Cites
Mediators and Mechanisms of Change in Psychotherapy Research
Kazdin, A. E. (2007) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091432 · Cited by 2,504 · cited 1×
“Therapeutic alliance is already known to be a major predictor of response in mental healthcare (Kazdin, 2007) and if the present thesis is correct, its influence is likely to be greater still in the context of psychedelics (see Carhart-Harris and Nutt, 2017).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 4×
“Indirect support for this may be found in the not inconsiderable (before-versus-after treatment) effects sizes observed in control conditions in recent double-blind randomised control trials of psilocybin for end-of-life distress, for example (Griffiths et al., 2016).”
BackgroundMethodInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“In model 1, it can be seen that: (a) feeling ready to ‘surrender’ to the experience, (b) having a clear intention for it, (c) having the experience in a therapeutic setting, and (d) taking a higher dose, are all predictive of having a certain kind of psychedelic experience which we label ‘peak’ – an intentionally secu…”
BackgroundCaspi, A., Hariri, A. R., Holmes, A., Uher, R., & Moffitt, T. E. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09101452 · Cited by 1,346
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Religions, Values, and Peak-Experiences
Jones, R. G., & Maslow, A. H. (1965) · Journal for the Scientific Study of Religion · doi:10.2307/1384286 · Cited by 949
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Self-citation
Research works printed but not linked: 10
- Aixala M, 2017, Psychotherapeutic Intervention in Integration of Difficult Psychedelic Experiences: The ICEERS Support Service
- Albarelli HP, 2009, A Terrible Mistake: The Murder of Frank Olson and the CIA’s Secret Cold War Experiments
- Hartogsohn I, 2015, The Psycho-Social Construction of LSD: How Set and Setting Shaped the American Psychedelic Experience 1950–1970
- Hartogsohn I, 2017, Drug Sci Pol Law, 3, 1
- Hofmann A, 1980, LSD: My Problem Child
- Krebs TS, 2012, J Psychopharmacol, 26, 994
- Lee MA, 1992, Acid Dreams: The Complete Social History of LSD, the CIA, the Sixties and Beyond
- Schwartz C (2017) Molly at the Marriott: Inside America’s Premier Psychedelics conference. The New York Times. Available at: https://www.nytimes.com/2017/05/06/style/psychedelic-drug-resurgence-daily-life.html (accessed 6 May 2017).
- Sos P, 2013, Neuro Endocrinol Lett, 34, 287
- Waldman A, 2017, A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life
Cited by
Sorted by citations
Items 201–300 of 655
Luoma, J. B., Shahar, B., Lear, M. K., Pilecki, B. C., & Wagner, A. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2824 · Cited by 29
Psychedelic innovations and the crisis of psychopharmacology
Langlitz, N. (2022) · BioSocieties · doi:10.1057/s41292-022-00294-4 · Cited by 24
Meir, P., Taylor, L., Soares, J. C., & Meyer, T. D. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.050 · Cited by 25
Okano, L., Jones, G., Deyo, B., Brandenburg, A., & Hale, W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.965641 · Cited by 24
Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs
Tagliazucchi, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.812227 · Cited by 25
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24
Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
Messell, C., Summer, L., Bonde, L. O., Beck, B. D., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.873455 · Cited by 30
Kaminski, D., & Reinert, J. P. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231205645 · Cited by 27
Bornemann, J. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1761573 · Cited by 24
Psychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 26
Self-citationPredictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 32
Greń, J., Tylš, F., Lasocik, M., & Kiraly, C. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1054692 · Cited by 29
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 24
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 22
Set and setting in microdosing: an oft-overlooked principle
Hartogsohn, I., & Petranker, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06249-8 · Cited by 26
Rankaduwa, S., & Owen, A. M. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad001 · Cited by 23
Hübner, S., Haijen, E. C. H. M., Kaelen, M., Carhart-Harris, R. L., & Kettner, H. (2021) · Journal of Medical Internet Research · doi:10.2196/25973 · Cited by 20
Self-citationTagliazucchi, E., Zamberlán, F., Cavanna, F., de la Fuente, L., Romero, C., Perl, Y. S., & Pallavicini, C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.720066 · Cited by 27
Family, N., Hendricks, P. S., Williams, L. T. J., Luke, D. P., Maillet, É. L., Maillet, É. L., & Raz, S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069103 · Cited by 23
Inter-individual variability in neural response to low doses of LSD
Hutten, N. R. P. W., Quaedflieg, C. W. E. M., Mason, N. L., Theunissen, E. L., Liechti, M. E., Duthaler, U., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03013-8 · Cited by 22
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 27
Self-citationThe psychedelic renaissance: the next trip for psychiatry?
Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. (2019) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2019.39 · Cited by 21
Šabanović, M., Lazari, A., Blanco-Pozo, M., Tisca, C., Tachrount, M., Martins-Bach, A. B., Lerch, J. P., Walton, M. E., & Bannerman, D. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02439-2 · Cited by 23
Viña, S. M. (2024) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-024-02023-y · Cited by 21
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P. C., Ley, L., Straumann, I., Becker, A., Müller, F., Arikci, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03074-9 · Cited by 25
Fischer, S., Gardini, E., Haas, F., & Cleare, A. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.11.009 · Cited by 21
Sweet, P. L., & Giffort, D. M. (2020) · Social Studies of Science · doi:10.1177/0306312720970282 · Cited by 17
Social identity processes as a vehicle for therapeutic success in psychedelic treatment
Newson, M., Haslam, S. A., Haslam, C., Cruwys, T., & Roseman, L. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00302-5 · Cited by 21
Self-citationKritzer, M. D., Pae, C., & Masand, P. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2069749 · Cited by 20
Rocha, J. M., Reis, J. A. S., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01590-1 · Cited by 20
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 22
Forstmann, M., Kettner, H., Sagioglou, C., Irvine, A., Gandy, S., Carhart-Harris, R. L., & Luke, D. P. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221146356 · Cited by 21
Self-citationPsychedelics and workplace harm
Viña, S. M., & Stephens, A. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1186541 · Cited by 19
Modlin, N. L., Creed, M., Sarang, M., Maggio, C., Rucker, J., & Williamson, V. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s432537 · Cited by 23
Psychedelics and the ‘inner healer’: Myth or mechanism?
Peill, J. M., Marguilho, M., Erritzøe, D., Barba, T., Greenway, K. T., Rosas, F. E., Timmermann, C., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241239206 · Cited by 24
Self-citationCalder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20
“…experiences vary depending not only on individual characteristics, such as health status, but also on the type of preparation available, intentions agreed upon before the experience, and the environment in which the experience takes place (Carhart-Harris et al., 2018; Golden et al., 2022).”
BackgroundDo psychedelics facilitate emergence of unconscious psychological processes
Lindegaard, T. (2023) · Psychodynamic Psychiatry · doi:10.1521/pdps.2023.51.3.270 · Cited by 18
Psychedelic therapy – refining the claim of a paradigm shift
Aicher, H. D., Wolff, M., & Herwig, U. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2410853 · Cited by 15
Hutchison, K. E., Hooper, J. F., & Karoly, H. C. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3038 · Cited by 21
How Psychedelic-Assisted Treatment Works in the Bayesian Brain
Villiger, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.812180 · Cited by 21
Technology and addiction: What drugs can teach us about digital media
Hartogsohn, I., & Vudka, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221105116 · Cited by 18
Branchi, I., Viglione, A., Vai, B., Cirulli, F., Benedetti, F., & Poggini, S. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103923 · Cited by 18
Self-citationConcurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Psychedelics and psychotherapy: is the whole greater than the sum of its parts
Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3050 · Cited by 17
Validation of the imperial psychedelic predictor scale
Angyus, M., Osborn, S., Haijen, E. C. H. M., Erritzøe, D., Peill, J. M., Lyons, T., Kettner, H., & Carhart-Harris, R. L. (2024) · Psychological Medicine · doi:10.1017/s0033291724002204 · Cited by 20
Self-citationSet and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Estric, C., Duron, T., Kabani, S., & López‐Castromán, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338214 · Cited by 18
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 20
The psychedelic ritual as a technique of the self
Dupuis, D. (2022) · Hau Journal of Ethnographic Theory · doi:10.1086/719792 · Cited by 17
Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal
Cherniak, A. D., Brulin, J. G., Mikulincer, M., Östlind, S., Carhart-Harris, R. L., & Granqvist, P. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148061 · Cited by 25
Self-citationClassic Psychedelic Use and Current Meditation Practice
Simonsson, C., Chambers, R., Hendricks, P. S., Goldberg, S. B., Osika, W., Schlosser, M., Ryde, A., Christersson, E., & Simonsson, O. (2023) · Mindfulness · doi:10.1007/s12671-023-02103-w · Cited by 20
Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey
Roméo, B., Fauvel, B., Dejean, S., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2227171 · Cited by 17
Kamilar-Britt, P., Gordis, E. B., & Earleywine, M. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0020 · Cited by 18
Inserra, A., Piot, A., Gregorio, D. D., & Gobbi, G. (2023) · CNS Drugs · doi:10.1007/s40263-023-01008-5 · Cited by 19
Tap, S. C. (2024) · Addiction Biology · doi:10.1111/adb.13386 · Cited by 16
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 20
Natural Psychoplastogens As Antidepressant Agents
Benko, J., & Vranková, S. (2020) · Molecules · doi:10.3390/molecules25051172 · Cited by 17
Neural and subjective effects of inhaled DMT in natural settingsPreprint
Pallavicini, C., Cavanna, F., Zamberlán, F., de la Fuente, L. A., Perl, Y. S., Arias, M., Romero, C., Carhart-Harris, R. L., Timmermann, C., & Tagliazucchi, E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.19.258145 · Cited by 17
Self-citationBlinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Fauvel, B., Kangaslampi, S., Strika-Bruneau, L., Roméo, B., & Piolino, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2059796 · Cited by 36
Mian, M. N., Dinh, M. T., Coker, A. R., Mitchell, J., & Anderson, B. T. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230787 · Cited by 16
Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study
Verroust, V., Zafar, R. R., & Spriggs, M. J. (2021) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2021.08.004 · Cited by 16
Schleim, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.906487 · Cited by 16
Body mass index (BMI) does not predict responses to psilocybin
Spriggs, M. J., Giribaldi, B., Lyons, T., Rosas, F. E., Kärtner, L., Buchborn, T., Douglass, H. M., Roseman, L., Timmermann, C., Erritzøe, D., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221131994 · Cited by 18
Self-citationLow, F., & Earleywine, M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2228303 · Cited by 17
Castillo, A., Dubois, J., Field, R. M., Fishburn, F. A., Gundran, A., Ho, W. C., Jawhar, S., Kates‐Harbeck, J., Aghajan, Z. M., Miller, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38258-8 · Cited by 16
Colli, C. D., Chiarotti, F., Campolongo, P., Giuliani, A., & Branchi, I. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00192-z · Cited by 16
Self-citationBridging the gap between single receptor type activity and whole‐brain dynamics
Jancke, D., Herlitze, S., Kringelbach, M. L., & Deco, G. (2021) · FEBS Journal · doi:10.1111/febs.15855 · Cited by 17
Harding, F., Seynaeve, M., Keeler, J. L., Himmerich, H., Treasure, J. L., & Kan, C. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2003059 · Cited by 16
Aixalà, M., Oña, G., Parés, Ò., & Bouso, J. C. (2019) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2019.1611739 · Cited by 18
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 16
Females in Psychedelic Research: A Perspective for Advancing Research and Practice
Cohen, Z. Z., & Blest‐Hopley, G. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00255 · Cited by 16
Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
Bennett, R., Yavorsky, C., & BRAVO, G. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.867484 · Cited by 15
Biomarkers of stress resilience: A review
Paribello, P., Branchi, I., Viglione, A., Mancini, G. F., Morena, M., Campolongo, P., & Manchia, M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104052 · Cited by 17
Self-citationPsychedelics align brain activity with context
Stoliker, D., Novelli, L., Khajehnejad, M. A., Biabani, M., Greaves, M. D., Barta, T., Williams, M., Chopra, S., Bazin, O., Simonsson, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10910-z · Cited by 18
Self-citationEvens, R., Reiche, S., Marek, R. M., Moon, D. U., Groß, R. E., Romanello, A., Masah, D. J., Scicchitano, M., Gutwinski, S., Montag, C., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.732028 · Cited by 15
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy
Florineth, G. A., Klima, I., Boeker, A. L., Catzeflis, P., Wopfner, A., Denier, N., Bracht, T., Adorjan, K., Pfammatter, M., Müller, F., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.54843 · Cited by 14
The association between naturalistic use of psychedelics and co-occurring substance use disorders
Rabinowitz, J., Lev‐Ran, S., & Gross, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1066369 · Cited by 15
Wang, K., Sun, Y., Nava, B., Sampiere, L., & Jacobs, R. J. (2023) · Cureus · doi:10.7759/cureus.37450 · Cited by 14
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 14
Orlowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231216322 · Cited by 15
Butlen‐Ducuing, F., Haberkamp, M., Aislaitner, G., Bałkowiec-Iskra, E., Mattila, T. K., Doucet, M. V., Kollb-Sielecka, M., Balabanov, P., Leuchs, A., & Elferink, A. J. A. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.2479 · Cited by 14
Diminished psychedelic returns on distress: Marital status and household size
Viña, S. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0293675 · Cited by 16
Global Drug SurveyPreprint
Petranker, R., Anderson, T., Maier, L. J., Barratt, M. J., Ferris, J., & WINSTOCK, A. R. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/xb8ve · Cited by 14
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13
“Contextual factors are commonly labeled as the set and setting [88].”
BackgroundKey competencies for psychedelic treatment in real-world mental health care settings
Wolff, M., Rutrecht, H. M., Gründer, G., Jungaberle, A., & Jungaberle, H. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.09.003 · Cited by 15
Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies
Chambers, R., Stoliker, D., & Simonsson, O. (2023) · Mindfulness · doi:10.1007/s12671-023-02206-4 · Cited by 14
Pouyan, N., Sisi, F. Y., Kargar, A., Scheidegger, M., McIntyre, R. S., & Morrow, J. D. (2023) · CNS Drugs · doi:10.1007/s40263-023-01044-1 · Cited by 13
Branchi, I. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16331 · Cited by 13
Self-citationAtiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 16
How to Make Psychedelic-Assisted Therapy Safer
Villiger, D. (2024) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180124000604 · Cited by 13
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy
Roseman, L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241309611 · Cited by 13
Self-citationA potential role for psilocybin in the treatment of obsessive-compulsive disorder
Jacobs, E. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00128 · Cited by 17
Leptourgos, P., Bouttier, V., Denève, S., & Jardri, R. (2021) · PsyArXiv (OSF Preprints) · doi:10.1016/j.neubiorev.2022.104593 · Cited by 16
Pattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Self-citationReframing psychedelic regulation: Tools, not treatments
Wolff, M., Gukasyan, N., Roseman, L., & Liknaitzky, P. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251348272 · Cited by 12
Self-citationPsychedelic therapy as reality transformation: A phenomenological approach
Petrement, M. S. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00231 · Cited by 12
On Redescribing the Indescribable: Trauma, Psychoanalysis and Psychedelic Therapy
Modlin, N. L., Stubley, J., Maggio, C., & Rucker, J. (2023) · British Journal of Psychotherapy · doi:10.1111/bjp.12852 · Cited by 11
Psychedelic use and psychological flexibility: The role of meaningful intention and decentering
Campo, W. M., & Yali, A. M. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00350 · Cited by 12
Jones, G. M., Lowe, M. X., Nayak, S. M., Sepeda, N. D., Kettner, H., Carhart-Harris, R. L., Jackson, H., & Garcia‐Romeu, A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.058 · Cited by 12
Self-citationZhou, K., de Wied, D., Carhart-Harris, R. L., & Kettner, H. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgae560 · Cited by 23
Self-citation
Metadata
- Authors
- Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M.
- Affiliations
- Imperial College London (GB)
- Psychedelic Research Group, Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK
- Istituto Superiore di Sanità (IT)
- Corresponding author
- Carhart-Harris, Robin L
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-02-15
- Volume
- 32
- Issue
- 7
- Pages
- 725-731
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2788854095
- Cited by
- 657
- References
- 62
- Citations by year
- 2026: 83 · 2025: 102 · 2024: 112 · 2023: 105 · 2022: 97 · 2021: 72 · 2020: 49 · 2019: 24 · 2018: 13
- FWCI
- 46.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research (ACF-2013-21-501)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, set and setting, context effects, 5-HT2A receptor agonism, neuroplasticity, long-term mental health outcomes, harm reduction
- MeSH terms
- Animals, Clinical Trials as Topic, Hallucinogens, Humans, Research Design, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
